We are live on ! Find out more
TAK icon

Takeda Pharmaceutical

303 hedge funds and large institutions have $953M invested in Takeda Pharmaceutical in 2024 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 100 increasing their positions, 93 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,520% more call options, than puts

Call options by funds: $22.9M | Put options by funds: $496K

8% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 93

0% more funds holding

Funds holding: 302 → 303 (+1)

0.13% less ownership

Funds ownership: 2.4% → 2.27% (-0.13%)

19% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 43

35% less capital inflows, than outflows

Capital inflows: $110M | Capital outflows: $170M

Holders
303
Holders Change
+1
Holders Change %
+0.33%
% of All Funds
3.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
35
Increased
100
Reduced
93
Closed
43
Calls
$22.9​M
Puts
$496​K
Net Calls
+$22.4​M
Net Calls Change
-⁠$3.36​M

TAK Hedge Fund Activity: Q4 2024 in Review

303 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2024, worth a combined $953M — down 6.1% from $1.02B a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of TAK and 35 opened new positions — a net loss of 8 holders — while 93 trimmed existing stakes and 100 added.

The largest buyer was UBS Group, adding an estimated $21.8M. The largest seller was Mondrian Investment Partners, cutting an estimated $70M.

  • 303 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2024, up from 302 in Q3 2024.
  • Funds reported $953M of Takeda Pharmaceutical stock for Q4 2024, down 6.1% quarter-over-quarter.
  • 35 funds opened new Takeda Pharmaceutical positions in Q4 2024 and 43 closed out, a net change of -8 holders.
  • The largest Takeda Pharmaceutical buyer in Q4 2024 was UBS Group, an estimated $21.8M added.
  • The largest Takeda Pharmaceutical seller in Q4 2024 was Mondrian Investment Partners, an estimated $70M sold.

Based on aggregated 13F filings for Q4 2024.